Abstract
The intense competition for resources to combat COVID-19 has greatly reduced access to health care for patients with other diseases. After the disastrous overrun of hospitals through COVID-19 patients in some jurisdictions, availability of resources for ‘elective’ medical procedures, including care for the chronically ill, has been greatly reduced in many places as a pre-emptive measure before or during the blooming of infection clusters. Pharmaceutical companies have either stopped recruitment or even cancelled ongoing clinical trials in chronic diseases. Pre-emptive triage and its impact on medical ethics is discussed in the framework of care for inflammatory bowel disease.
Keywords: Crohn disease; drug development; ethics; registration trial; regulatory trials; ulcerative colitis.
【저자키워드】 Drug development, Ethics, Crohn disease, registration trial, regulatory trials, ulcerative colitis, 【초록키워드】 COVID-19, clinical trial, Health care, Drug development, hospital, Infection, Ethics, Inflammatory bowel disease, Regulatory, Crohn disease, Health, Patient, Clusters, recruitment, resource, Care, ulcerative colitis, framework, COVID-19 patient, in some, medical procedures, pharmaceutical companies, Pharmaceutical Company, Chronic diseases, other diseases, reduced, 【제목키워드】 COVID-19, clinical, Act, Stopping,